AIMS This meta-analysis was conducted to investigate the fracture risk among patients with T2DM treated with sulfonylurea. METHODS The PubMed and other databases were searched for eligible studies. Both randomized controlled trials and observational studies that compared the fracture risk of sulfonylurea to other hypoglycemic agents were included. Pooled risk ratios and 95% confidence intervals were calculated. Subgroup analysis and meta-regression analyses were conducted to explore the source of heterogeneity. RESULTS A total of 11 studies involving 255,644 individuals were included in our meta-analysis. In comparing sulfonylurea users with patients who had not taken sulfonylurea, the pooled risk ratio for developing fracture was 1.14 (95% confifidence interval, 1.08-1.19). In subgroup analyses, the pooled risk ratio of bone fracture in patients receiving sulfonylurea versus thiazolidinedione, metformin and insulin was 0.90 (95% CI, 0.76-1.06), 1.25 (95% CI, 1.18-1.32) and 0.81 (95% CI, 0.74-0.89) respectively. Meta regression showed that age and gender were not related to the effect of sulfonylurea on fracture. CONCLUSIONS Sulfonylurea use was associated with 14% increase in the risk of developing fracture in T2DM. The risk of fracture caused by sulfonylurea was similar to thiazolidinedione, higher than metformin and lower than insulin.

中文翻译：

---

2型糖尿病患者的磺脲类药物和骨折风险：一项荟萃分析。

目的这项荟萃分析旨在研究磺脲类药物治疗的T2DM患者的骨折风险。方法检索PubMed和其他数据库以寻找符合条件的研究。包括将磺酰脲与其他降糖药比较的骨折风险的随机对照试验和观察性研究。计算汇总的风险比率和95％的置信区间。进行了亚组分析和元回归分析，以探索异质性的来源。结果我们的荟萃分析共包括11项研究，涉及255,644人。在将磺脲类药物使用者与未服用磺酰脲类药物的患者进行比较时，合并发生骨折的风险比为1.14（95％可信区间为1.08-1.19）。在亚组分析中，磺脲类药物与噻唑烷二酮，二甲双胍和胰岛素患者合并骨折的风险比分别为0.90（95％CI，0.76-1.06），1.25（95％CI，1.18-1.32）和0.81（95％CI，0.74-0.89）分别。荟萃回归显示，年龄和性别与磺脲类药物对骨折的影响无关。结论使用磺脲类药物可使T2DM发生骨折的风险增加14％。磺酰脲类引起的骨折风险与噻唑烷二酮相似，高于二甲双胍，低于胰岛素。结论使用磺脲类药物可使T2DM发生骨折的风险增加14％。磺酰脲类引起的骨折风险与噻唑烷二酮相似，高于二甲双胍，低于胰岛素。结论使用磺脲类药物可使T2DM发生骨折的风险增加14％。磺酰脲类引起的骨折风险与噻唑烷二酮相似，高于二甲双胍，低于胰岛素。